Determination of Itopride and Its N-oxide in Biological Fluids by High-Performance Liquid Chromatography with Positive Ion Electrospray Ionization Tandem Mass Spectrometric Detection
Guihai Chen,Dan Hao,Minghong Tan,Zhi-rong,Youguang Guo,Shen Dong,Xin Yao,Kan Yang,Zhi,Quan Zhou,Hong-hao
2007-01-01
Abstract:AIM: Itopride, which is a dopamine D2 antagonist with acetylcholinesterase inhibitory actions, is often prescribed for patients with functional dyspepsia. The primary metabolite in humans is the N-oxide, generated by oxidation of the tertiary amine N-dimethyl group. The urinary excretions of itopride and its N-oxide were 3.7% and 75.4%, respectively, in healthy subjects after a single oral administration at a therapeutic dose. Studies support a predominant role of FMO3 in the formation of itopride N-oxide in human liver microsomes. In addition, itopride appears to be a suitable probe for human liver FMO3. Our aim was to establish a simple method adopting a one-step liquid-liquid extraction with dichloromethane followed by high-performance liquid chromatography (HPLC) with positive ion electrospray ionization tandem mass spectrometric (ESI-MS/MS) detection to simultaneously determine itopride and its N-oxide in human plasma and urine for FMO3 pharmacogenetics study, using sulpiride as an internal standard (IS). METHODS: Acquisition was performed in multiple reaction monitoring (MRM) mode, by monitoring the transitions: m/z 360.1166.4 for itopride, m/z 376.1165.5 for itopride N-oxide and m/z 342.9112.2 for IS, respectively. Analytes were chromatographed on an Intersil ODS-3 reverse-phase chromatographic column (2.1 mm×150 mm, 5 μm) by isocratic elution with water (1000 mL water added 1 mL formic acid)-acetonitrile (60∶40, v/v), the flow rate was 0.2 mL/min with a total analysis time of 3 min per run. RESULTS: The linearity for itopride and its N-oxide were in the range of 0.25-1 000 ng/mL and 0.5-1 000 ng/mL, respectively, both in plasma and urine (r2=0.999). The recovery of itopride was 95.8% for plasma and 101.2% for urine and that of itopride N-oxide was 90.4% for plasma and 98.4% for urine. The intra-and inter-day RSD were 15% both in plasma and urine. CONCLUSION: The method described is successfully applied to the analysis of itopride and its N-oxide in plasma and urine samples generated after administration of 50 mg itopride hydrochloride in 18 healthy male volunteers who were genetyped according to FMO3 genetic polymorphism.